Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Thyssen, Jacob P. ^{[2
]}

Guttman-Yassky, Emma ^{[3
]}

Bieber, Thomas ^{[4
]}

Carrascosa, Jose Manuel ^{[5
]}

Simpson, Eric ^{[6
]}

Rosmarin, David ^{[7
]}

Elmaraghy, Hany ^{[8
]}

Meskimen, Eric ^{[8
]}

Natalie, Chitra R. ^{[8
]}

Liu, Zhuqing ^{[8
]}

Xu, Chenjia ^{[8
]}

Pierce, Evangeline ^{[8
]}

Morgan-Cox, MaryAnn ^{[8
]}

Silverberg, Jonathan, I ^{[9
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR 97223 USA

[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark

[3] Icahn Sch Med Mt Sinai, New York, NY USA

[4] Univ Hosp Bonn, Bonn, Germany

[5] UAB, Germans Trias i Pujol Univ Hosp, IGTP, Barcelona, Spain

[6] Oregon Hlth & Sci Univ, Portland, OR USA

[7] Tufts Univ, Sch Med, Boston, MA USA

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷

关键词：

monotherapy; atopic dermatitis; moderate-to-severe; lebrikizumab; interleukin (IL)-13;

D O I：

10.1093/bjd/ljac140.018

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

322

引用

页数：2

共 50 条

[1] Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
Simpson, Eric
Fernandez-Penas, Pablo
de Bruin-Weller, Marjolein
Lio, Peter A.
Chu, Chia-Yu
Ezzedine, Khaled
Agell, Helena
Casillas, Marta
Ding, Yuxin
Yang, Fan Emily
Pierce, Evangeline
Bieber, Thomas
ADVANCES IN THERAPY, 2025, 42 (01) : 132 - 143
[2] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Amy S. Paller
Carsten Flohr
Lawrence F. Eichenfield
Alan D. Irvine
Jamie Weisman
Jennifer Soung
Ana Pinto Correia
Chitra R. Natalie
Claudia Rodriguez Capriles
Evangeline Pierce
Sarah Reifeis
Renata Gontijo Lima
Clara Armengol Tubau
Vivian Laquer
Stephan Weidinger
Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534
[3] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Paller, Amy S.
Flohr, Carsten
Eichenfield, Lawrence F. F.
Irvine, Alan D. D.
Weisman, Jamie
Soung, Jennifer
Correia, Ana Pinto
Natalie, Chitra R. R.
Capriles, Claudia Rodriguez
Pierce, Evangeline
Reifeis, Sarah
Lima, Renata Gontijo
Tubau, Clara Armengol
Laquer, Vivian
Weidinger, Stephan
DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
[4] Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Blauvelt, Andrew
Kircik, Leon
Schlesinger, Todd
Pierce, Evangeline
Burge, Russel
Behling, Michael
Atwater, Amber Reck
Elmaraghy, Hany
Armstrong, April
JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
[5] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide A.
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan D.
Pierce, Evangeline
Elmaraghy, Hany
Pillai, Sreekumar
Dawson, Zach
Chen, Sherry
Armengol, Clara
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
[6] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[7] Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Guttman-Yassky, Emma
Silverberg, Jonathan I.
Nemoto, Osamu
Forman, Seth B.
Wilke, August
Prescilla, Randy
de la Pena, Amparo
Nunes, Fabio P.
Janes, Jonathan
Gamalo, Margaret
Donley, David
Paik, Jim
DeLozier, Amy M.
Nickoloff, Brian J.
Simpson, Eric L.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (04) : 913 - +
[8] A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis
Gooderham, Melinda
Lynde, Charles
Alam, Maryam Shayesteh
Sadick, Neil
Rohan, Craig A.
Werschler, William Philip
Hebert, Adelaide A.
Laquer, Vivian T.
Sauder, Maxwell
Del Rosso, James Q.
Rodgers, Timothy
Tan, Ricardo
Schleicher, Stephen
Murrell, Dedee F.
Fernandez-Penas, Pablo
Reich, Adam
Gkalpakiotis, Spyridon
Ruiz, Juan Ruano
Wollenberg, Andreas
Szepietowski, Jacek C.
Sticherling, Michael
Weyergraf, Ansgar J.
Hadzavdic, Suzana Ljubojevic
Baran, Wojciech
Vilchez, Trinidad Montero
Eniko, Telegdy
Sebastian, Michael
Chaudhry, Sohail
Lee, Zachary
Yu, Danni
Liu, Yi
Waltz, Wang
Gilbert, Jenny
Elko-Simms, Lucinda M.
Fanton, Christie
Jue, Charleen
Tagliaferri, Mary
Zalevsky, Jonathan
Rosmarin, David
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 105 - 107
[9] Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials
Zirwas, Matthew J.
Boguniewicz, Mark
Rosmarin, David
Fuxench, Zelma Chiesa
Warren, Richard B.
Torres, Tiago
de Bruin-Weller, Marjolein
Dawson, Zach
Atwater, Amber Reck
Elmaraghy, Hany
Pierce, Evangeline
Bardolet, Laia
Zhong, Jinglin
Armstrong, April W.
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 54 - 56
[10] Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
Katoh, Norito
Tanaka, Akio
Takahashi, Hidetoshi
Shimizu, Ryosuke
Kataoka, Yoko
Torisu-Itakura, Hitoe
Morisaki, Yoji
Igawa, Ken
CURRENT MEDICAL RESEARCH AND OPINION, 2025, 41 (01) : 1 - 12

← 1 2 3 4 5 →